According to a notice in the Federal register the New Jersey-based contractor has asked to be registered as a bulk supplier of Dihydromorphine and Hydromorphone.
The notice states that Halo – which was registered by the DEA in March - plans to manufacture Hydromorphone HCl for sale to other manufacturers and to manufacture other controlled substances for distribution to its customers.
In other news, Halo completed the acquisition a manufacturing site in Montreal, Canada from Teva and has signed a five-year manufacturing contract.
Under the deal Halo manufacture the range of non-sterile creams, ointments and liquid drugs produced at the site until Teva transfers some of them to its plant in Stouffville, Ontario at the end of the year.
In the longer term Halo will continue to make some drugs at the facility on Teva’s behalf. All Teva 350 staff will continue to work at the site until 2013 at which point around 152 are expected to join the contract manufacturing organisation’s (CMO) staff.
Teva had been trying to sell the facility since shortly after it acquired as part of its $3.6bn takeover of German generic drugmaker Ratiopharm in 2010.
The Israeli generics firm did plan to shutter the plant sometime this year, but Halo agreed to take it off its hands in March.